FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of September 2011

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨            No  x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

 

 

 

In September 2011, Sanofi issued the press releases attached hereto as Exhibit 99.1 to 99.3 which are incorporated herein by reference.

Exhibit List

 

Exhibit

No.

   

Description

Exhibit 99.1

    Press release dated September 12, 2011: Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes.

Exhibit 99.2

    Press release dated September 12, 2011: Initiation of Lantus leads to better glycemic control at similar weight gain versus other comparators in patients with Type 2 Diabetes

Exhibit 99.3

    Press release dated September 19, 2011: U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin® Patent Litigation

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: September 19, 2011     SANOFI
  By  

/S/ John Felitti

  Name:   John Felitti
  Title:   Associate Vice President,
    Corporate Law, Financial & Securities Law

 

3

Exhibit Index

 

Exhibit

No.

   

Description

Exhibit 99.1

    Press release dated September 12, 2011: Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes.

Exhibit 99.2

    Press release dated September 12, 2011: Initiation of Lantus leads to better glycemic control at similar weight gain versus other comparators in patients with Type 2 Diabetes

Exhibit 99.3

    Press release dated September 19, 2011: U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin® Patent Litigation

 

4